ArticleCancers2019
Plasma Metabolomics Identifies Lipid and Amino Acid Markers of Weight Loss in Patients with Upper Gastrointestinal Cancer.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Identification of Circulating Lipidomic Biomarkers of Malnutrition Risk among Oncology Patients in the Total Cancer Care (TCC) Study: A Cross-Sectional Analysis.The Journal of nutrition · 2026Article
- Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer.Journal of cachexia, sarcopenia and muscle · 2026Article
- Multi-omics profiling of cachexia-targeted tissues reveals a spatio-temporally coordinated response to cancer.Nature metabolism · 2026Article
- Cachexia-induced reprogramming of visceral organ metabolism by human pancreatic cancer xenografts.International journal of cancer · 2025Article
- Serum metabolomics analysis of malnutrition in patients with gastric cancer: a cross sectional study.BMC cancer · 2024Article
- Cancer cachexia: biomarkers and the influence of age.Molecular oncology · 2024Review
- A molecular pathway for cancer cachexia-induced muscle atrophy revealed at single-nucleus resolution.Cell reports · 2024Article
- Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.Cancers · 2024Review
- Oncometabolite D-2-hydroxyglutarate-dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia.Communications biology · 2023Article
- Review
- Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Quantitative Comparison of Statistical Methods for Analyzing Human Metabolomics Data.Metabolites · 2022Article
- Article
- Metabolomics and its Applications in Cancer Cachexia.Frontiers in molecular biosciences · 2022Review
- Metabolomics as an Important Tool for Determining the Mechanisms of Human Skeletal Muscle Deconditioning.International journal of molecular sciences · 2021Review
- Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients.Journal of cachexia, sarcopenia and muscle · 2021Observational
- Metabolic Biomarkers for the Early Detection of Cancer Cachexia.Frontiers in cell and developmental biology · 2021Article
- Systematic Survey of the Alteration of the Faecal Microbiota in Rats With Gastrointestinal Disorder and Modulation by Multicomponent Drugs.Frontiers in pharmacology · 2021Review
- High levels of modified ceramides are a defining feature of murine and human cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Cachexia is a multifactorial wasting syndrome associated with high morbidity and mortality in patients with cancer. Diagnosis can be difficult and, in the clinical situation, usually relies upon reported weight loss. The 'omics' technologies allow us the opportunity to study the end points of many biological processes. Among these, blood-based metabolomics is a promising method to investigate the pathophysiology of human cancer cachexia and identify candidate biomarkers. In this study, we performed liquid chromatography mass spectrometry (LC/MS)-based metabolomics to investigate the metabolic profile of cancer-associated weight loss. Non-selected patients undergoing surgery with curative intent for upper gastrointestinal cancer were recruited. Fasting plasma samples were taken at induction of anaesthesia. LC/MS analysis showed that 6 metabolites were highly discriminative of weight loss. Specifically, a combination profile of LysoPC 18.2, L-Proline, Hexadecanoic acid, Octadecanoic acid, Phenylalanine and LysoPC 16:1 showed close correlation for eight weight-losing samples (≥5% weight loss) and nine weight-stable samples (<5%weight loss) between predicted and actual weight change (r = 0.976,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.